( CAMBRIDGE Mass.--(BUSINESS WIRE)--Jun ...)Gloucester Pharmaceuticals Reports Positive Interim Phase II Data,on Romidepsin for T-Cell Lymphomas at the 2007 American Society of,Clinical Oncology Annual Meeting,Health

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun 5, 2007 - Gloucester Pharmaceuticals, Inc., a privately held cancer therapeutics development company, today announced that data for romidepsin as a treatment for cutaneous T-cell lymphoma (CTCL) and peripheral T-cell lymphoma (PTCL) were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting being held in Chicago, IL. The data presented are part of an interim analysis of a phase II study of romidepsin sponsored by the National Cancer Institute (NCI) under a Cooperative Research and Development Agreement (CRADA) with Gloucester.

Data from the NCI's ongoing clinical trial of romidepsin was presented in Abstract #8027 "Phase II Trial of Depsipeptide in Patients with Cutaneous T-Cell Lymphoma and Relapsed Peripheral T-Cell Lymphoma" on Monday, June 4th.

The interim results reported on 70 patients with CTCL and 39 patients with PTCL. In the CTCL patient group 4 of 70 patients, or 6%, achieved a complete response, with the duration of response ranging from 8 to 63+ months. A partial response was observed in 18 of 70 patients, or 26%, with the duration of response ranging from 1 to 69+ months. The most common adverse events reported were nausea, vomiting, fatigue, transient granulocytopenia and thrombocytopenia, and anorexia.

Commenting on the data from the NCI's study, William McCulloch, M.B., FRCP, Executive Vice President and Chief Medical Officer at Gloucester said, "Clinical evidence for romidepsin's value in the treatment of T-cell lymphomas continues to build. Based on the data from this trial, as well as interim data from our own Gloucester-sponsored CTCL pivotal phase II study which is nearing completion, we remain enthusiastic about the clinical prospects for romidepsin."

In the PTCL patient group 3 of 39 patients, or 7%, achieved a complete response, with the duration of response ranging from 9 to 43+ months. A partial respons
'"/>

Page: 1 2 3
Related medicine technology :

1. Gloucester Pharmaceuticals Receives Fast Track Designation for Romidepsin in Peripheral T-Cell Lymphoma
2. Gloucester Pharmaceuticals Reports on Romidepsin and Erlotinib Combination in Non-Small Cell Lung Cancer Presented at American Association of Cancer Research Annual Meeting
3. Gloucester Pharmaceuticals Announces Multiple Presentations of Preclinical Romidepsin Data at American Association of Cancer Research Annual Meeting
4. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
5. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
7. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
8. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
9. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
10. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
11. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea